Welcome to our dedicated page for Silvaco Group SEC filings (Ticker: SVCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you open a Silvaco Group filing you’re not just reading any tech report—you’re decoding how its TCAD, EDA and semiconductor IP tools turn silicon physics into recurring SaaS revenue. Locating details on R&D intensity, software licensing backlogs or intangible IP amortization inside a 200-page 10-K can be challenging. That’s where Stock Titan’s AI-powered summaries step in, turning dense disclosures into plain-English insights in seconds.
Need the latest Silvaco Group quarterly earnings report 10-Q filing or want to track executives’ stock sales before a new simulation release? Our platform streams every form as it hits EDGAR, then highlights what matters—segment growth for TCAD versus SIP, cash-flow swings from deferred revenue, and risk factors tied to semiconductor cycles. Real-time alerts on Silvaco Group Form 4 insider transactions mean you’ll see buys and sells as soon as they’re filed, while AI context explains whether the transactions relate to equity compensation, option exercises or strategic share sales.
Whether you’re comparing year-over-year R&D ratios, reviewing acquisition footnotes in an 8-K, or preparing questions on executive pay for proxy season, our expert analysis keeps the critical data at your fingertips. Common searches we already answer include:
- Silvaco Group insider trading Form 4 transactions
- Silvaco Group SEC filings explained simply
- understanding Silvaco Group SEC documents with AI
- Silvaco Group executive stock transactions Form 4
- Silvaco Group annual report 10-K simplified
- Silvaco Group earnings report filing analysis
- Silvaco Group proxy statement executive compensation
- Silvaco Group 8-K material events explained
- Silvaco Group quarterly earnings report 10-Q filing
- Silvaco Group Form 4 insider transactions real-time
Stop scrolling through PDFs—let AI surface the story behind Silvaco Group’s numbers so you can make decisions faster and with confidence.
Silvaco Group, Inc. announced that Christopher Zegarelli will join as Chief Financial Officer effective September 15, 2025. His base salary is $450,000 and he is eligible for a $400,000 sign-on bonus paid in two $200,000 installments, the first payable within 30 days of the start date and subject to repayment if he voluntarily resigns or is terminated for cause before January 1, 2027. The second installment is contingent on achieving fiscal 2026 revenue and profit targets at or above 100% of plan and continued service through December 31, 2026. He is eligible for an annual incentive target equal to 60% of base salary, prorated for 2025, with payment based on company-wide performance and at the Board's discretion. He will receive RSUs equal to $2,300,000 in value with 1/4 vesting after one year and the balance vesting quarterly to fully vest at year four. He is eligible for the Executive Severance Plan and an indemnification agreement. The company disclosed the appointment via a press release furnished as Exhibit 99.1.
Silvaco Group, Inc. reported a CEO transition and related compensation arrangements. Dr. Babak A. Taheri stepped down as CEO and director, effective August 19, 2025, and entered a Separation Agreement providing severance and other benefits. Under that agreement he will receive aggregate cash severance of $975,484 (equal to 18 months' base salary plus pro‑rata target bonus), COBRA health benefit payments for 15 months, accelerated vesting of 126,161 unvested time‑based restricted stock units, 12 months of car lease payments totaling $12,000, and payment of a $20,000 life insurance premium. The agreement also preserves confidentiality, non‑disparagement and non‑solicit covenants and includes a release of claims.
The Board appointed Dr. Walden C. Rhines as CEO, effective August 19, 2025, and the company entered an employment agreement through March 31, 2027. Dr. Rhines will receive an annual base salary of $160,000 and may receive performance‑based restricted stock unit grants with grant‑date fair values ranging from $100,000 up to an aggregate of $6,252,636, vesting upon achievement of specified VWAP trading thresholds and continued employment through the Term. If terminated under certain conditions before or at the end of the Term, Dr. Rhines may be eligible for a lump sum severance ranging from $500,000 to $1,000,000 and accelerated vesting of PRSUs, subject to a release and covenant compliance.
Form 4 summary: Taheri Babak A., listed as Chief Executive Officer and Director of Silvaco Group, Inc. (SVCO), reported a change in beneficial ownership on 08/13/2025. The filing shows a disposition of 9,155 shares of common stock at a price of $4.65 per share under transaction code F. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, the reporting person beneficially owned 773,157 shares on a direct basis. The form was signed by Candace Jackson as attorney-in-fact on 08/14/2025.
FAQ
What is the current stock price of Silvaco Group (SVCO)?
What is the market cap of Silvaco Group (SVCO)?
